Frequency Therapeutics (NASDAQ: FREQ) is a clinical-stage biotech company currently conducting multiple clinical trials on FX-322, a hearing loss drug that is notably Frequency's only product in clinical development. Although final phase 2a results have yet to be released, interim results released in March were convoluted, and the stock price fell from $36 to $8 as a result . As of April 14, the stock price is currently at about $10.
Image source: Getty Images.
The various current clinical trials for FX-322 are examining it as a treatment for different causes of hearing loss. The phase 2a trial focused mainly on two populations: noise-induced sensorineural hearing loss and mild to moderately severe sensorineural hearing loss. Sensorineural hearing loss is caused by damage to inner ear structures of the auditory nerve and accounts for 90% of all cases of hearing loss in adults. In this instance and various others, Frequency hopes to treat the loss of hearing by using FX-322 to stimulate progenitor cells in the cochlea to grow into new hair cells.
For further details see:
Are Disappointing Results an Opportunity for Frequency Therapeutics Investors?